Nutraceutix Announces Issuance of CDT Patent; Second Patent Added to Nutraceutix IP Portfolio in Drug Delivery.

Business Editors, Health/Medical Writers

REDMOND, Wash.--(BW HealthWire)--Feb. 7, 2002

Nutraceutix, Inc. (OTCBB: NUTX), has received notification from the United States Patent Office of the January 8, 2002 issuance of the dual polymer CDT(TM) patent (#6,337,091). The dual polymer Controlled Delivery Technology (CDT) platform is one of two issued patents for modified oral dosage release systems licensed exclusively by Nutraceutix from Temple University, Philadelphia. In collaboration with Dr. Reza Fassihi of Temple University School of Pharmacy, Nutraceutix has been developing dietary supplements, OTC products and prescription drugs which employ these novel delivery system concepts as embodied in the two CDT patents.

The CDT technology, recently commercialized in its first product available through major Canadian retail pharmacy chains, has also been successfully deployed in prototype formulations of established pharmaceuticals, such as nifedipine, theophylline, propanolol, diltiazem, and verapamil. In addition, the technology has allowed Nutraceutix to cost-effectively develop formulations for the OTC and nutritional industries, such as: glucosamine, glucosamine/chondroitin, niacin, pseudoephedrine, caffeine, vitamin C, Novasoy(R), and other difficult compounds and branded ingredients. According to David T. Howard, President and CEO of Nutraceutix, Inc., "The new CDT dual polymer patent in conjunction with the previously issued CDT salt patent and our recently filed third CDT patent application provides Nutraceutix with three novel drug delivery platforms. Nutraceutix is currently addressing some of the most challenging hurdles of oral drug delivery: difficult to tablet ingredients, zero order kinetics (linear release), and poorly soluble active ingredients. Combined with dramatically lower cost of production, these three CDT platforms constitute a compelling reason for OTC, nutraceutical and pharmaceutical companies to partner with Nutraceutix for their controlled delivery systems."

Among the important advantages the CDT platform offers manufacturers are the cost-effectiveness of scale-up and production, and the technology's self-correcting feature, which permits an increased degree of control not achievable with first generation drug delivery systems.

Based in Redmond, Washington, Nutraceutix, Inc. is a biopharmaceutical company leveraging specialized knowledge, proprietary and patented products and technologies such as LiveBac(R) Probiotics and the patented CDT(TM) Controlled Delivery Technology platform to introduce distinctive and novel OTC products, prescription drugs and dietary supplements.

Nutraceutix technologies provide distinctive products with tangible benefits for the consumer and competitive commercial advantages for licensees. Established partnerships with pharmaceutical, OTC and natural products industry companies enable Nutraceutix to co-develop new products and to add value and protection to existing product franchises. For more information on Nutraceutix, please call 1.800.548.3222 or visit http://www.nutraceutix.com/.

Novasoy(R) is a registered trademark of Archer Daniels Midland Company; Decatur, IL.

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company's ability to continue to successfully market and provide its products and services and maintain their effectiveness, the continuation of the arrangements with the Company's product development partners, the ability of the Company to meet its financial projections, and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements whether as a result of new information or otherwise.